# Ilya Budik

> Ilya Budik is the CEO of CardioRenal Systems, a Milford, Massachusetts medical device company behind the RenalPro System (sold as RenalGuard outside the U.S.), a technology built to prevent acute kidney injury in cardiac surgery, interventional cardiology, and ICU patients. A medtech executive with roughly a decade of experience across strategy, finance, and business development, he has steered the company through FDA Breakthrough Device Designation, CE Mark approval abroad, and an FDA IDE approval clearing the way for a U.S. pivotal trial. He previously led the neurodiagnostics company NeuroQuest and worked in innovation strategy and healthcare finance.

- **Role:** CEO at CardioRenal Systems, Inc.
- **Organizations:** CardioRenal Systems, Inc. (RenalGuard / RenalPro), Imagine Bio, NeuroQuest, MND Diagnostic Ltd., Ethicon Endo-Surgery
- **Education:** Finance and Biochemistry, Miami University (Ohio), Healthcare Entrepreneurship - Lahav Executive Training, Tel Aviv University
- **Known for:** Led CardioRenal Systems to FDA Breakthrough Device Designation for RenalGuard Therapy (January 2023), Secured FDA Investigational Device Exemption (IDE) approval to begin a U.S. pivotal trial of RenalPro (2026), Attracted a strategic investment from St. Elizabeth Healthcare and the Angel Physicians Fund

## Career timeline

- **—** — Global finance role at Ethicon Endo-Surgery
- **—** — Business development at MND Diagnostic Ltd.
- **—** — CEO of NeuroQuest, developing diagnostics for Alzheimer's and ALS
- **—** — Managing Partner at Imagine Bio, an innovation strategy consultancy
- **—** — CEO of CardioRenal Systems, Inc. (RenalGuard / RenalPro)
- **2023** — RenalGuard Therapy receives FDA Breakthrough Device Designation for cardiac surgery-associated AKI
- **2026** — CardioRenal secures FDA IDE approval and strategic hospital investment to begin a U.S. pivotal trial of RenalPro

## Achievements

- Led CardioRenal Systems to FDA Breakthrough Device Designation for RenalGuard Therapy (January 2023)
- Secured FDA Investigational Device Exemption (IDE) approval to begin a U.S. pivotal trial of RenalPro (2026)
- Attracted a strategic investment from St. Elizabeth Healthcare and the Angel Physicians Fund
- Advanced a technology protected by roughly 20 patents and pending applications
- Backed by clinical evidence including the 220-patient KIDNEY Study showing a 52% reduction in AKI versus standard of care

## Latest updates

- **2026-07** — CardioRenal Systems secured FDA IDE approval and a strategic hospital investment to begin enrollment in a U.S. pivotal trial of RenalPro for cardiac surgery-associated AKI.
- **2023-01** — RenalGuard Therapy received FDA Breakthrough Device Designation for prevention of cardiac surgery-associated AKI.

## Links

- Website: https://cardiorenalsystems.com
- LinkedIn: https://www.linkedin.com/in/ibudik/

---

Profile page: https://yespress.io/ilya-budik
Published by YesPress — https://yespress.io
Last updated: 2026-07-17